I spent a couple of hours on Sunday objectively going over every announcement since relist. I looked at it from the perspective of a potential investor who knew nothing about TIS or the re-birthed FTT. Would I invest? For me, the answer was yes. I did not see anything to suggest the results will be anything other than what the trial was specifically designed to achieve. That is not the same thing as saying there was, or is nothing.
Right from the outset there has been a common thread of quiet confidence in the work being done. As the trial has progressed, that confidence has only increased, evidenced not only by the quality of the information released, but more recently with regard to how the company is preparing for business post-readout.
That's just my take on it. Don't know if I have mentioned it before, but I also held TIS, very small in comparison, but costly nonetheless. I have learned a lot since then. At least, I hope I have. My postion now is one of looking forward to Factor Therapeutics taking its place as an all too rare Australian biotech success story.